Share Name Share Symbol Market Type Share ISIN Share Description
Diurnal Grp LSE:DNL London Ordinary Share GB00BDB6Q760 ORD GBP0.05
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 195.00p 194.00p 196.00p 195.00p 195.00p 195.00p 0 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -12.2 -18.0 - 119.61

Diurnal Group PLC Appointment of NOMAD and Joint Broker

18/05/2018 1:11pm

UK Regulatory (RNS & others)


Diurnal Grp (LSE:DNL)
Historical Stock Chart

1 Month : From Apr 2018 to May 2018

Click Here for more Diurnal Grp Charts.

TIDMDNL

RNS Number : 5487O

Diurnal Group PLC

18 May 2018

18 May 2018

Diurnal Group plc

("Diurnal" or the "Company")

Appointment of NOMAD and Joint Broker

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the appointment of Panmure Gordon (UK) Limited (Panmure) as Nominated Adviser to the Company and Cantor Fitzgerald Europe as joint broker to the Company, with immediate effect. Panmure remains joint broker to the Company.

 
 For further information, please visit www.diurnal.co.uk 
  or contact: 
 
                                                +44 (0)20 
 Diurnal Group plc                               3727 1000 
 Martin Whitaker, Chief Executive 
  Officer 
 Richard Bungay, Chief Financial Officer 
 
 Panmure Gordon (UK) Limited (Nominated         +44 (0) 20 
  Adviser and Joint Broker)                      7886 2500 
 Corporate Finance: Freddy Crossley, 
  Emma Earl 
 Corporate Broking: James Stearns 
 
                                                +44 (0) 20 
 Cantor Fitzgerald Europe (Joint Broker)         7894 7000 
 Corporate Finance: Phil Davies, Will 
  Goode, Michael Boot 
 Healthcare Equity Sales: Andrew Keith 
 
 FTI Consulting (Media and Investor             +44 (0)20 
  Relations)                                     3727 1000 
 Simon Conway 
 Victoria Foster Mitchell 
 

Notes to Editors

About Diurnal

Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

For further information about Diurnal, please visit www.diurnal.co.uk

This information is provided by RNS

The company news service from the London Stock Exchange

END

APPLIFITERITLIT

(END) Dow Jones Newswires

May 18, 2018 08:11 ET (12:11 GMT)

1 Year Diurnal Grp Chart

1 Year Diurnal Grp Chart

1 Month Diurnal Grp Chart

1 Month Diurnal Grp Chart
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V:gb D:20180526 08:24:58